Lehi, Utah — October 6, 2025 — Leads & Copy — Halia Therapeutics, a clinical-stage biopharmaceutical company focused on anti-inflammatory therapies, has appointed Paul Jones as Chief Strategy Officer & GM, International Markets. Jones will spearhead the acceleration of GENMOR-AI, Halia’s AI platform for identifying genetic modifiers of disease, while strengthening the company’s partnership with the Department of Health – Abu Dhabi.
According to Halia Therapeutics CEO, David Bearss, Jones’s experience in genomics initiatives, including the UK’s 100,000 Genomes Project and the Emirati Genome Programme, makes him a valuable addition to the leadership team.
Jones brings 30 years of life sciences experience, with expertise in genomics, digital health, precision medicine, and public-private health innovation.
Before joining Halia, Jones served as CEO of the Omics Centre of Excellence at M42 in Abu Dhabi and held leadership roles at Illumina, Genomics England, Cisco, Novartis, IMS Health, and PwC.
Jones’s appointment supports Halia’s APOE4 program in Alzheimer’s disease, utilizing GENMOR-AI to identify resilience mechanisms for new therapies.
Halia Therapeutics is focused on developing therapies that target the root causes of inflammation. Halia’s mission is to create data-driven therapies that not only extend life but also improve its quality.
Contact Information:
Taylor Avei
Director of Business Development
Halia Therapeutics
info@haliatx.com
+1 (385) 355-4315
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
Source: Halia Therapeutics
